{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-095094","form_type":"8-K","ticker":"PMVP","cik":"0001699382","company_name":"PMV Pharmaceuticals, Inc.","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.931312+00:00","generated_at":"2026-05-15T18:48:26.945660+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"PMV Pharma reports FY2025 net loss of $77.7M; reaffirms NDA filing for rezatapopt in Q1 2027","bullets":["Cash and securities $112.9M at Dec 2025 (down from $183.3M); runway to end of Q2 2027.","Net loss $77.7M for FY2025 vs $58.7M in 2024; net cash used in ops $73.6M (vs $51.3M).","R&D expenses $69.9M (up from $58.5M) on rezatapopt trial costs; G&A $16.3M (down from $26.9M).","PYNNACLE Phase 2 enrollment on track; NDA submission for ovarian cancer planned Q1 2027.","Rezatapopt granted FDA Orphan Drug Designation for TP53 Y220C positive ovarian cancer; Phase 1 in NEJM."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-095094","json":"https://secwatch.observer/filing/0001193125-26-095094.json","markdown":"https://secwatch.observer/filing/0001193125-26-095094.md","text":"https://secwatch.observer/filing/0001193125-26-095094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526095094/0001193125-26-095094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526095094/pmvp-20260306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:48:26.945660+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"833ef9ed628e664758264ae9cbb968765fc1db3b","claim":"PMV Pharmaceuticals, Inc. reported the full year ended December 31, 2025 results: net income Net loss for the year ended December 31, 2025, was $77.7 million.","evidence_excerpt":"On March 6, 2026, PMV Pharmaceuticals, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1699382/000119312526095094/0001193125-26-095094-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Net income","value":"Net loss for the year ended December 31, 2025, was $77.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}